Quais são as opções de tratamento para o antigénio leucocitário humano (HLA) B27-associativo à artrite reactiva?

Anna Luisa Di Lorenzo, MBBCh Professora Assistente Clínica, Departamento de Oftalmologia, Kresge Eye Institute, Wayne State University School of Medicine; Consultores, Somerset Ophthalmology
Anna Luisa Di Lorenzo, MBBCh é membro das seguintes sociedades médicas: American Academy of Ophthalmology, American College of Physicians, American Medical Association, American Society of Cataract and Refractive Surgery, Association for Research in Vision and Ophthalmology, Michigan Society of Eye Physicians & Cirurgiões, Michigan State Medical Society, Oakland County Medical Society, Women in Ophthalmology, Inc>br>Disclosure: Nada a revelar.

div> Conselho Editorial Especializado

Simon K Law, MD, PharmD Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine
Simon K Law, MD, PharmD é membro das seguintes sociedades médicas: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Glaucoma Society
Disclosure: Nothing to disclose.

p>R Christopher Walton, MD Professor Adjunto, Departamento de Oftalmologia, University of Texas Health Science Center em San Antonio
R Christopher Walton, MD é um membro das seguintes sociedades médicas: American Academy of Ophthalmology, American Uveitis Society
Disclosure: Nada a revelar.div> Editor Chefe p>Andrew A Dahl, MD, FACS Professor Assistente de Cirurgia (Oftalmologia), New York College of Medicine (NYCOM); Director de Formação em Oftalmologia de Residência, The Institute for Family Health and Mid-Hudson Family Practice Residency Program; Staff Ophthalmologist, Telluride Medical Center
Andrew A Dahl, MD, FACS é membro das seguintes sociedades médicas: American Academy of Ophthalmology, American College of Surgeons, American Intraocular Lens Society, American Medical Association, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, Medical Society of the State of New York, New York State Ophthalmological Society, Outpatient Ophthalmic Surgery Society
Disclosure: Nada a revelar.div> Contribuintes adicionais p>John D Sheppard, Jr, MD, MMSc Professor de Oftalmologia, Microbiologia e Biologia Molecular, Director Clínico, Thomas R Lee Center for Ocular Pharmacology, Director do Programa de Investigação de Residência em Oftalmologia, Escola Médica da Virginia Oriental; Presidente, Virginia Eye Consultants
John D Sheppard, Jr, MD, MMSc é membro das seguintes sociedades médicas: American Academy of Ophthalmology, American Society for Microbiology, American Society of Cataract and Refractive Surgery, American Uveitis Society, Association for Research in Vision and Ophthalmology
Disclosure: Serve(d) como director, oficial, sócio, empregado, conselheiro, consultor ou curador para: 1-800-DOCTORS; AbbVie; Alcon; Aldeyra; Alergan; Alphaeon; ArcScan; Baush+Lomb; Bio-Tissue; Clearside; EyeGate; Hovione; Mededicus; NovaBay; Omeros; Pentavision; Portage; Santen; Science Based Health; Senju; Shire; Sun Pharma; TearLab;TearScience;Topivert<br/>Serve(d) como orador ou membro de um gabinete de oradores para: AbbVie; Alcon; Allergan; Bausch+Lomb; Bio-tissue; EyeGate; Hovione; LayerBio; NovaBay; Omeros; Portage; Santen; Shire; Stemnion; Sun Pharma; TearLab; TearScience; Topivert <br/>Subsídio de investigação recebido de Alcon; Aldeyra; alergan; Baush+ Lomb; EyeGate; Hovione; Kala; Ocular Therapeutix; Pfizer; RPS; Santen; Senju; Shire; Topcon; Xoma.